Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals sells CARDAMYST, a nasal spray for treating a rapid heartbeat condition called PSVT. It last closed at $0.42 on Nov 17, up 15.12% on the day. MIST last reported earnings on Fri, Nov 13, 2026. The average 12-month price target from 4 analysts is $4.25 (+911.4% from the last close), with a high of $6.00 and a low of $3.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From MIST's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 4 analysts who set a price target on MIST in the past 90 days. The average target is $4.25, with a high of $6.00 and a low of $3.00, compared with the last close of $0.42.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | TD Cowen | Maintained | Buy | $5 |
| Nov 16 | Piper Sandler | Maintained | Buy | $3 |
| Nov 16 | HC Wainwright & Co. | Maintained | Buy | $6 |
| Aug 20 | Cantor Fitzgerald | Initiated | Buy | $3 |
Technical Analysis
The stock is 60% below its 20 day and 84% below its 50 day average. It is 208% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), oversold. The nearest support is the Pivot at $0.42, and the nearest resistance the Pivot R1 at $0.46.
| RSI (14) | 29.90 | Oversold below 30 | Oversold |
| MACD | -0.08 | Below its signal line | Bearish |
| Stochastic | 6.2 | Near the bottom of its range | Oversold |
| ADX (14) | 28.6 | Trending down | |
| Williams %R | -87.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -246.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −44.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.08 | Typical daily range, 19.3% of price |
| RSI (14) | 27.46 | Oversold below 30 | Oversold |
| MACD | -0.24 | Below its signal line | Bearish |
| Stochastic | 9.7 | Near the bottom of its range | Oversold |
| ADX (14) | 27.3 | Trending down | |
| Williams %R | -93.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -158.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −57.1% | Change over 10 sessions | Bearish |
| ATR (14) | $0.19 | Typical daily range, 44.2% of price |
What happened before
See how MIST did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How MIST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in MIST in the last 90 days.
MIST Institutional Ownership
Full report →- ●27 buying vs 28 selling
- ●Held by funds -0.4 pts
- ▼Funds holding -4
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 74 | 78 | −5.1% |
| In funds' top 10 | 3 | 3 | 0.0% |
| Held by funds | 40.5% | 40.8% | −0.4 pts |
| New / increased | 12 / 15 | 6 / 23 | −6.9% |
| Reduced / sold out | 15 / 13 | 23 / 13 | −22.2% |
| Put/call ratio | – | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MIST is in one of them and how their past MIST trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MIST in an article yet. Here's the latest on the wider market.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company based in Montreal, Quebec, Canada, that develops heart medicines. Its main product is CARDAMYST, a nasal spray containing etripamil that patients can use themselves to stop an episode of PSVT, a condition that causes the heart to suddenly beat too fast. The product is sold in the United States through retail pharmacies, and the company is developing etripamil for atrial fibrillation as well. Its customers are patients and the doctors, mainly cardiologists, who prescribe its medicines.
- Headquarters
- Montreal, Quebec, Canada


